Usted buscó: polyarthritis (Inglés - Maltés)

polyarthritis caused by susceptible escherichia coli.
polyarthritis ikkawżat minn escherichia coli.

arthritis (joint swelling, polyarthritis and joint effusion)
artrite (nefħa fil-ġogi, poliartrite u effużjoni mill-ġogi)

treatment of septicaemia, polyarthritis or polyserositis associated with streptococcus suis infection.
trattament ta’ septisimja, poliartrite u poliserusite assoċjati ma’ infezzjoni b’ streptococcus suis.

polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in patients from the age of 2 years
poliartrite (fattur rewmatojde pożittiv jew negattiv) u oligoartrite estiża f'pazjenti li għandhom minn sentejn 'il fuq

quinidine at higher doses has also been associated with a lupus-like syndrome involving polyarthritis, sometimes with a positive antinuclear antibody test.
quinidine f’dożi ogħla kien assoċjat ukoll ma’ sindromu jixbah il-lupus li jinvolvi poliartrite, xi drabi b’test pożittiv tal-antikorpi antinukleari.

in juvenile idiopathic polyarthritis, roactemra given by infusion has been compared with placebo in one main study involving 166 children from 2 years of age who could not take or had inadequate response to methotrexate.
fil-poliartrite idjopatika ġovanili, roactemra mogħti b’infużjoni tqabbel ma’ plaċebo fi studju wieħed li involva 166 tifel u tifla minn sentejn 'il fuq li ma setgħux jingħataw il-metotressat jew li ma kellhomx rispons tajjeb għalih.

roactemra can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of rheumatoid arthritis, active systemic juvenile idiopathic arthritis or juvenile idiopathic polyarthritis.
roactemra jista' jinkiseb biss b'riċetta tat-tabib u l-kura jenħtieġ tinbeda minn tabib li jkollu l- esperjenza fid-dijanjożi u fil-kura tal-artrite rewmatojde, tal-artrite idjopatika ġovanili sistematika attiva jew tal-poliartrite idjopatika ġovanili.

potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly.
Ġew irrappurtati b’mod mhux komuni reazzjonijiet li potenzjalment huma medjati mill- immunokumpless, bħalma huma reazzjoni tat-tip tal-mard tas-serum, poliartrite b’raxx u glomerulonefrite proliferattiva.

children with polyarticular course jia (rheumatoid factor positive or negative polyarthritis, extended oligoarthritis, juvenile psoriatic arthritis or systemic jia with no current systemic symptoms) were included in the study.
tfal b’jia bi żvilupp poliartikulari (poliartrite b’fattur rewmatojde pożittiv jew negattiv, oligoartrite estiża, artrite psorjatika tat-tfal u ż-żgħażagħ jew jia sistemika li attwalment m’għandhiex sintomi sistemiċi) ġew inklużi fl-istudju.

certain forms of juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints) in the following groups: patients aged two to 17 years who have polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis and have not responded adequately to or cannot take methotrexate;
ċerti forom tal-artrite idjopatika ġuvenili (marda rari li tfeġġ fit-tfulija li tikkawża infjammazzjoni ta’ ħafna ġogi) fil-gruppi li ġejjin: pazjenti li għandhom bejn sentejn u 17-il sena li jkollhom poliartrite (fattur tar- rewmatojde pożittiv jew negattiv) u oligoartrite estiża u li ma jkunux irrispondew b’mod adegwat għall-metotressat jew li ma jistgħux jiħduh;